ASTRO 2022 | The predictive & prognostic value of genomic adjusted radiation dose (GARD) for oropharyngeal cancer

Jacob Scott, MD, DPhil, Cleveland Clinic, Cleveland, OH, provides an overview of an investigation into the predictive value of the genomic adjusted radiation dose (GARD) on overall-survival (OS) in HPV-positive oropharyngeal squamous cell carcinoma (OPSCC) patients treated with radiotherapy. Gene expression profiled for 234 formalin-fixed paraffin-embedded (FFPE) samples were analyzed from patients with HPV+ OPSCC and GARD was calculated for each patient. Despite uniform radiation dose utilization, GARD showed significant heterogeneity, reflecting genomic differences in the cohort. For every individual unit increase of GARD we, a benefit to the patients survival and local control was observed. This interview took place at the American Society for Radiation Oncology (ASTRO) 2022 Congress in San Antonio, Tx.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.